Brown Brothers Harriman & Co’s Prime Medicine PRME Stock Holding History

Brown Brothers Harriman & Co’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,065	Closed	-$39K	–	1552
2024 Q3	$39K	Hold	10,065	–	–	﹤0.01%	843
2024 Q2	$51.7K	Hold	10,065	–	–	﹤0.01%	760
2024 Q1	$70.5K	Hold	10,065	–	–	﹤0.01%	702
2023 Q4	$89.2K	Hold	10,065	–	–	﹤0.01%	641
2023 Q3	$96K	Hold	10,065	–	–	﹤0.01%	602
2023 Q2	$147K	Buy	+10,065	New	+$141K	﹤0.01%	526

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Brown Brothers Harriman & Co's PRME Position: Q4 2024 in Review

Brown Brothers Harriman & Co sold out of Prime Medicine (PRME) in Q4 2024, closing a stake of 10,065 shares — an estimated $39K sold.

Brown Brothers Harriman & Co first reported a position in PRME in Q2 2023 and held it in 6 quarters. The position peaked at $147K in Q2 2023. 131 funds tracked by Wall St. Rank hold PRME as of Q4 2024.

Brown Brothers Harriman & Co reported no remaining Prime Medicine position as of Q4 2024 after selling out during the quarter.
Brown Brothers Harriman & Co sold 10,065 Prime Medicine shares in Q4 2024, an estimated $39K.
Brown Brothers Harriman & Co first reported a position in Prime Medicine in Q2 2023 and held it in 6 quarters.
Brown Brothers Harriman & Co's Prime Medicine position peaked at $147K in Q2 2023.
131 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2024.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2024, filed 12 Feb 2025.